- N Engl J Med 2022; 387:421-432
Prasinezumab is a monoclonal antibody to α-synuclein, a protein involved in the pathogenesis of Parkinson’s disease. In a placebo-controlled trial, prasinezumab did not slow the progression of disease over a period of 52 weeks.
- N Engl J Med 2022; 387:408-420
In a phase 2 trial in early Parkinson’s disease, treatment with cinpanemab, a monoclonal antibody to α-synuclein, did not affect clinical or imaging progression over a period of 72 weeks.
- N Engl J Med 2022; 387:466-467
Parkinson’s disease is increasing in incidence at a faster rate than any other serious neurologic condition.1 Despite multiple agents putatively showing preclinical promise, there is no disease-modifying therapy available for clinical use in this disorder. Indeed, no potential treatment has survived scrutiny in a clinical trial to reach...
- N Engl J Med 2022; 386:1339-1344
An implanted device (typically used to treat pain) that stimulates the thoracic spinal cord and sympathetic ganglia was coupled with accelerometers that detect changes in body position. With this device, a patient with multiple-system atrophy regained the ability to stand and walk without syncope (shown in a video).
- N Engl J Med 2020; 383:2501-2513
In a randomized, sham-controlled trial involving 40 patients, therapeutic lesions on one side in the subthalamic nucleus were produced by focused ultrasound. At 4 months, motor performance was better in the active-treatment group. Twelve patients had neurologic deficits, many of which resolved by 12 months.
- N Engl J Med 2020; 383:2582-2584
Parkinson’s disease causes progressive motor and cognitive dysfunction. Medications aim to replace deficient dopamine in the brain and reduce the characteristic slowness, stiffness, and tremor. However, as the disorder progresses, medications provide shorter duration of benefit and produce involuntary dyskinetic movements. Surgical approaches to Parkinson’s disease that can provide additional...
- N Engl J Med 2020; 382:1926-1932
Dopaminergic progenitor cells that were derived from a patient’s induced pluripotent stem cells were implanted bilaterally in the putamen. Clinical and PET studies suggested survival of the cells and clinical stability over a period of 24 months, without dyskinesias.
- N Engl J Med 2019; 380:705-707
Neither medicine nor society is prepared for the eventuality that most of us will outlive our driving life expectancy. To clinicians, driving may not seem like a medical problem, yet it is intertwined with health, medical care, and patient well-being on multiple levels.
- N Engl J Med 2019; 380:492-494
A recent study implicates the enzyme poly(adenosine 5′-diphosphate-ribose) polymerase 1 (PARP1) as a mediator of neuronal cell death in Parkinson’s disease. The findings also provide support for a class of FDA-approved drugs that inhibit PARP1, currently used in the treatment of certain breast and ovarian cancers, as candidate drugs for...
- N Engl J Med 2019; 380:315-324
In a randomized, delayed-start trial of levodopa in Parkinson’s disease, with one group receiving the drug for 80 weeks and the other starting at 40 weeks, the difference between the groups in the progression of symptoms was not significant.
- N Engl J Med 2019; 380:389-390
Patients with Parkinson’s disease and the neurologists who treat them have had a complicated relationship with levodopa. Despite the undisputed efficacy of levodopa in ameliorating the cardinal motor signs of bradykinesia and rigidity, how and when to initiate treatment have been controversial issues. The practice of delaying and restricting, or...
- N Engl J Med 2014; 371:1369-1373
The research of Alim Benabid and Mahlon DeLong — just recognized with the Lasker–Debakey Clinical Medical Research Award — has led to improved lives for more than 100,000 people with Parkinson's disease or other neurologic or neuropsychiatric disorders.
- N Engl J Med 2013; 369:2236-2251
Mitochondria fuse and divide in response to cell demands and environment. Alterations in mitochondrial dynamics underlie various human diseases, including cancer and neurologic and cardiovascular diseases. Defining the alterations may identify potential therapeutic targets.
- N Engl J Med 2013; 369:233-244
Multiple-system atrophy is a rare neurodegenerative disease characterized by autonomic failure. Mutations affecting an enzyme essential for the synthesis of coenzyme Q10 confer susceptibility to the disease in some persons.
- N Engl J Med 2013; 368:610-622
In this 2-year trial involving patients with Parkinson's disease and early motor complications, subthalamic stimulation plus medical therapy resulted in better quality of life and motor function than medical therapy alone.
- N Engl J Med 2013; 368:651-662
This review discusses the cellular process of autophagy (“self-eating”), which plays key roles in normal development of the immune system and adaptation to stress, as well as in a wide range of disease states.
- N Engl J Med 2013; 368:675-676
Parkinson's disease is a chronic, progressively disabling neurodegenerative disorder that occurs late in life, causing motor, autonomic, emotional, and cognitive symptoms. The cost of Parkinson's disease is substantial, including reduced quality of life, lost productivity, and increased health care expenditures. The number of persons with Parkinson's disease worldwide is, conservatively,...
- N Engl J Med 2013; 368:543-550
Four siblings with gait dystonia and other neurologic deficits were found to have a mutation in SLC18A2, a gene encoding a transporter of serotonin and dopamine. Administration of an agonist of the dopamine receptor was followed by a marked improvement in symptoms.
- N Engl J Med 2012; 367:1529-1538
A 72-year-old man with Parkinson's disease is referred for consideration of deep-brain stimulation, which involves the implantation of electrodes in one of the nuclei of the basal ganglia and can result in significant improvement in some symptoms of Parkinson's disease.
- N Engl J Med 2012; 366:2126-2128
Dementias such as Alzheimer's disease and frontotemporal dementia are thought to spread from one part of the brain to another. Two recent studies suggest that a protein-templating mechanism underlies the spread of disease in at least a subgroup of these dementias.